Research Article

Sparfloxacin-Metal Complexes as Urease Inhibitors: Their Synthesis, Characterization, Antimicrobial, and Antienzymatic Evaluation

Table 6

(a) Inhibition zones (mm) against C. albicans. (b) Inhibition zones (mm) against F. solani. (c) Inhibition zones (mm) against T. rubrum.
(a)

Complexes Concentrations (μgmL−1)
5102040

SPFX7.21 ± 0.215.3 ± 0.2116.31 ± 0.0417.28 ± 0.11
S128.09 ± 0.36** (−12.21)9.29 ± 0.1** (39.28)11.1 ± 0.08** (31.94)14.05 ± 0.25** (18.69)
S138.84 ± 0.16** (−22.61)11.01 ± 0.27** (28.04)15.08 ± 0.18** (7.54)18.32 ± 0.14** (−6.02)
S140 ± 0** (100)0 ± 0** (100)9.31 ± 0.25** (42.92)10.28 ± 0.23** (40.51)
S156.97 ± 0.07** (3.33)10.16 ± 0.2** (33.59)12.21 ± 0.12** (25.14)14.37 ± 0.06** (16.84)
ANOVA
(df = 10, 22)
F-270.407 F-26.145 F-78.461 F-52.516

Mean ± S.D (percent zone of inhibition), ** , * .
(b)

ComplexesConcentrations (μgmL−1)
5102040

SPFX0 ± 00 ± 010.2 ± 0.0411.12 ± 0.07
S1220.23 ± 0.24** (0)22.2 ± 0.22** (0)23.29 ± 0.06** (−128.33)27.06 ± 0.2** (−143.35)
S1322.06 ± 0.06** (0)24.06 ± 0.15** (0)28.22 ± 0.09** (−176.67)30.04 ± 0.02** (−170.14)
S1412.09 ± 0.22** (0)15.98 ± 0.04** (0)21.17 ± 0.35** (−107.55)24.24 ± 0.06** (−117.99)
S1517.26 ± 0.14** (0)22.03 ± 0.27** (0)26.08 ± 0.16** (−155.69)30.13 ± 0.2** (−170.95)
ANOVA
(df = 10, 22)
F-67.16 F-124.599 F-246.703 F-133.773

Mean ± S.D (percent zone of inhibition), ** , * .
(c)

ComplexesConcentrations (μgmL−1)
5102040

SPFX0 ± 020.4 ± 0.0723.07 ± 0.0524.29 ± 0.13
S1222.22 ± 0.14** (0)22.07 ± 0.4** (−8.19)24.24 ± 0.15** (−5.07)27.06 ± 0.09** (−11.4)
S1318.95 ± 0.37** (0)25.31 ± 0.07** (−24.07)26.27 ± 0.27** (−13.87)27.08 ± 0.31** (−11.49)
S1412.22 ± 0.09** (0)17.02 ± 0.17** (16.57)19.11 ± 0.08** (17.17)22.18 ± 0.07** (8.69)
S1518.24 ± 0.1** (0)21.32 ± 0.17** (−4.51)24.1 ± 0.03** (−4.46)27.25 ± 0.19** (−12.19)
ANOVA
(df = 10, 22)
F-252.324 F-2663.194 F-476.634 F-315.709

Mean ± S.D (percent zone of inhibition), ** , * .